# Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects

> **NCT06151808** · NA · COMPLETED · sponsor: **Sinotau Pharmaceutical Group** · enrollment: 42 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** XTR006

## Key facts

- **NCT ID:** NCT06151808
- **Lead sponsor:** Sinotau Pharmaceutical Group
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-01
- **Primary completion:** 2023-11-28
- **Final completion:** 2024-01-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06151808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06151808, "Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06151808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*